What's new? Log in Free sign up

Ventyx Biosciences (VTYX) News and press releases

Company Profile

News

From Benzinga Pro

Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis

Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet

The Latest Analyst Ratings for Ventyx Biosciences

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Ventyx Biosciences, Maintains $54 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Buy and maintains $54 price target.

Recap: Ventyx Biosciences Q1 Earnings

Ventyx Biosciences Q1 EPS $(0.68) Misses $(0.65) Estimate

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 51.11 percent decrease over losses of $(0.45) per share

Earnings Scheduled For May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.

Preview: Ventyx Biosciences's Earnings

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names

Trading Ideas, ETFs

Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is upon us, yet the S&P 500 has been largely stagnant in recent trading sessions.

Credit Suisse Reiterates Outperform on Ventyx Biosciences, Maintains $63 Price Target

News, Price Target, Reiteration, Analyst Ratings

Credit Suisse analyst Tiago Fauth reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Outperform and maintains $63 price target.

Oppenheimer Maintains Outperform on Ventyx Biosciences, Lowers Price Target to $62

News, Price Target, Analyst Ratings

Oppenheimer analyst Jeff Jones maintains Ventyx Biosciences (NASDAQ:VTYX) with a Outperform and lowers the price target from $65 to $62.

Ventyx Biosciences Q4 EPS $(0.62) Misses $(0.61) Estimate

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.61) by 1.64 percent. This is a 44.19 percent decrease over losses of $(0.43) per share

Earnings Scheduled For March 23, 2023

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.

Ventyx Biosciences's Earnings Outlook

Analyst Expectations for Ventyx Biosciences's Future

Analyst Ratings

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Wells Fargo Initiates Coverage On Ventyx Biosciences with Overweight Rating, Announces Price Target of $77

News, Price Target, Initiation, Analyst Ratings

Wells Fargo analyst Derek Archila initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Overweight rating and announces Price Target of $77.

HC Wainwright & Co. Reiterates Buy on Ventyx Biosciences, Maintains $50 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Buy and maintains $50 price target.

Press releases

From Benzinga Pro

Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis

Health Care, Press Releases, General

ENCINITAS, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

News, Press Releases

ENCINITAS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of

Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

Earnings, Press Releases

Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn's disease and psoriatic arthritis, with topline data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator)

Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

News, Press Releases

ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range

Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress

Earnings, Press Releases

Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn's disease and psoriatic arthritis, with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R

Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

News, Press Releases

ENCINITAS, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of

Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure

Markets, Press Releases

ENCINITAS, Calif., March 11, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), has learned that Silicon Valley Bank ("SVB") has been closed by the California Department of Financial Protection

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.